Navigation Links
Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
Date:4/15/2008

-No Metastatic Lesions Were Detectable After Combination Therapy Treatment-

-Survival Time More Than Doubled in Animals Treated with Combination

Therapy- -Established Tumors Regressed by 50% After Combination Therapy Treatment-

SAN DIEGO and TUSTIN, Calif., April 15 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that preclinical data presented at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) shows that a mouse equivalent of Peregrine's anti-phosphatidylserine (anti-PS) vascular targeting antibody bavituximab administered in combination with the chemotherapeutic agent docetaxel demonstrated excellent signs of efficacy in a preclinical model of hormone-refractory prostate cancer. These new data confirm and extend the results of previous studies of Peregrine's anti-PS antibodies in models of prostate cancer. They were described by researchers in an oral presentation at the AACR Annual Meeting at 2:10pm PDT on April 14, 2008 in San Diego, California.

Dr. Yi Yin, a postdoctoral researcher in the laboratory of Dr. Philip Thorpe, professor of pharmacology at the University of Texas Southwestern Medical Center at Dallas, reported that in a mouse model of hormone-refractory prostate cancer, the combination of the bavituximab equivalent antibody 2aG4 and the chemotherapy drug docetaxel significantly decreased the growth of tumors, eliminated detectable metastases and prevented tumor re-growth. This increase in anti-tumor efficacy and anti-metastatic activity was achieved w
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
2. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
3. PG500 Series Presented at the AACR Annual Meeting in San Diego
4. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
7. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
8. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
9. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
10. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
11. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... -,Phytopharm plc (LSE: PYM) ("Phytopharm" or the ... reverses the,changes in the area of the ... be presented by Dr Jonathan Brotchie, an,internationally ... International Congress of Parkinson's Disease and Movement,Disorders' ...
... UVIDEM was well-tolerated with signs of durable,disease control ... 05, 2007 /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. today presented ... vaccine clinical trial (DC-MEL-202). The,results showed that UVIDEM ... of immune response in patients with,progressive metastatic melanoma. ...
Cached Medicine Technology:Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 2Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 3Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 4Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 5IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 2IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 3IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 4IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 5
(Date:4/18/2014)... The Gerontologist reports that among ... a decrease in anxiety about death and increases in ... lives. In particular, listening to gospel music is associated ... increase in sense of control. , These associations are ... individuals of both low- and high-socioeconomic status. , The ...
(Date:4/18/2014)... (Seattle, WA April 18, 2014) Benaroya Research ... to research how blocking a particular molecule in metastatic ... and the number of lung metastases. BRI scientists have ... protein can shrink tumors by 60 - 80 percent ... to the lung. The $1.8 million five-year grant comes ...
(Date:4/18/2014)... scientists could lead to potential new treatments for breaking ... , Fibrosis, or scarring, is a hallmark of ... lungs can lead to serious organ damage and, in ... options centers on findings made by Swati Bhattacharyya, PhD, ... that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... relief targets that could be used to provide ... College London made the discovery when researching how ... the body. , Dr Marzia Malcangio said: "We ... generation and our findings could help chemotherapy patients ... potential side effect of some chemotherapy drugs (such ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2
... researchers at Mayo Clinic shows that obese patients with ... loss drug sibutramine, while others who lack these genetic ... are published in the October issue of Gastroenterology ... placebo-controlled study, Mayo researchers measured the impact of two ...
... who are part of an Asian-white ,couple face an ... in which both partners are white, according to a new ... University ,School of Medicine. , The researchers also found ... likely than white women with Asian or white partners to ...
... to help save more than 1 million children, Stores ... N.J., Sept. 30 Quarters found in the,bottom of purses, ... living and dying for needy children. The Vitamin Shoppe is ... save the life of a,child., Affecting up to 140 ...
... Turns to Medical Professional to Apply Rigors,of "Evidence-Based Medicine" ... Give Bad Advice About the Best Medicine For Portfolios?, ... expected to base their diagnoses on what the latest ... specific diseases and other,illnesses. Yet most financial advisors do ...
... Hits $178 Million Mark, WHITE PLAINS, N.Y., Sept. ... it has awarded a new Marshall A. Lichtman,Specialized Center ... Becker Professor of Medicine at Stanford University., Dr. ... year for five,years, for a total of $6.25 million. ...
... presidential debate history, a female nominee will take the stage ... new ground in 1984, it has taken 24 years for ... party ticket. On Thursday night, the nation will be watching ... in the vice presidential debate. A revealing study by a ...
Cached Medicine News:Health News:Genes affect weight loss drug effectiveness 2Health News:Asian-white couples face distinct pregnancy risks, Stanford/Packard 2Health News:Asian-white couples face distinct pregnancy risks, Stanford/Packard 3Health News:Spare Change Can Help Save the Life of a Child 2Health News:Spare Change Can Help Save the Life of a Child 3Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 2Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 3Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 4Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 5Health News:The Leukemia & Lymphoma Society Awards Major Grant to Stanford Researcher 2Health News:Gender is a relative term in politics, MU study finds 2
... MonoPrep LBP Processor is a primary component ... collection, accessioning, processing, sampling, and slide preparation ... management. The MonoPrep LBP Processor produces high-quality ... a broad range of cytology specimen types. ...
... quick and easy automated refill system ... space on your laboratory bench and ... easy-to-use, one-hand system, you only need ... of Diamond Tips. All sizes of ...
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
Medicine Products: